Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y

GlaxoSmithKline plcGSK , one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses.

This UK-based company now focuses on its three core businesses - Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products).

However, like many of its peers, Glaxo is facing challenges in the form of increasing competition, genericization and pricing pressure in major markets.

In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.

Glaxo's performance has been pretty good so far, with the company's earnings beating expectations thrice in the four trailing quarters. Overall, the company has delivered an average positive surprise of 8.96%.

Currently, Glaxo has a Zacks Rank #2 (Buy), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.

Revenues: Revenues were up 6% year over year at constant exchange rate (CER).

Key Stats: Sales in the quarter were driven by strong performance across all three business segments. The Consumer Healthcare and Vaccines segments were up 9% and 14%, respectively. The Pharmaceuticals segment was also up 3% at CER.

2017 Guidance: Glaxo expects core 2017 earnings growth of 5-7% at CER. This is based on an expected decline in 2017 US Advair sales of 15-20%.

Share Price Impact: In-active in pre-market trading .

Check back later for our full write up on GSK earnings report later!

GlaxoSmithKline PLC Price and EPS Surprise

GlaxoSmithKline PLC Price and EPS Surprise | GlaxoSmithKline PLC Quote

Just Released - Driverless Cars: Your Roadmap to Mega-Profits Today

In this latest Special Report, Zacks' Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making - autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline PLC (GSK): Get Free Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

Earnings Investing Stocks

Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More